Redmile Group, LLC

Redmile Group, LLC has demonstrated a clear buying bias in its recent insider trading activity, as evidenced by SEC Form 4 filings. Over the past year, Redmile executed 29 trades across two companies, with a total buy value of $14,999,996.70 and a total sell value of just $167,175.11. Notably, all 18 of its most recent trades were purchases, underscoring a consistent acquisition strategy. The majority of this activity has been concentrated in ADC Therapeutics SA (ADCT), with a significant $14,999,996.70 purchase on October 27, 2025, marking the largest single transaction in the dataset. Earlier in the year, Redmile also engaged in smaller transactions related to ADCT, including a $66,680.56 purchase on February 1, 2024, and a series of other acquisitions throughout January and February 2024. In addition to its focus on ADCT, Redmile has shown interest in Stoke Therapeutics, Inc. (STTK) and IGM Biosciences, Inc. (IGMS), though these transactions were primarily classified as acquisitions or dispositions with no reported monetary value. The absence of recent selling activity, coupled with the substantial buy volume, suggests a strategic accumulation of positions, particularly in ADCT. This pattern aligns with Redmile’s broader investment approach, which appears to prioritize long-term holdings over short-term divestments. The data reflects a deliberate and focused trading strategy, emphasizing equity accumulation in select companies.